Celltrion Expands European Business Through Broader Distribution Networks and Product Diversification
Celltrion is accelerating its expansion in Europe by diversifying distribution channels, broadening its product portfolio and strengthening country-specific sales strategies. The South Korean biopharmaceutical company is moving beyond its traditional hospital- and tender-focused business model to tap into pharmacy networks and establish additional revenue streams through recent…
Celltrion, a South Korean biopharmaceutical company, is expanding its European business through the diversification of distribution channels and product offerings. The company has recently acquired French healthcare company Gifrer and Swiss pharmaceutical distributor iQone, integrating their distribution capabilities and product portfolios into its operations.
This move aims to broaden revenue sources, particularly through pharmacy-based sales of biosimilars such as Stoboclo and Osenvelt. Additionally, Celltrion is strengthening its direct sales operations in individual European markets by tailoring strategies to local healthcare systems, demand patterns, and competitive conditions. Strong performance of key products like Omlyclo and Aptozma, along with successful supply tenders in the Netherlands, further supports the company's growth in the European market.
Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
